The advancement of regenerative technologies demands careful alignment with societal values, legal frameworks, and business viability. Ethical, regulatory, and commercial aspects address questions of patient consent, long-term safety, equitable access, and sustainability of emerging therapies. The global expansion of clinical trials and biotechnological innovation calls for harmonized approval processes and transparent standards. Commercial strategies must balance profitability with public good, encouraging innovation while maintaining accountability. Ethical, regulatory, and commercial aspects also include intellectual property rights, pricing models, and education for both clinicians and patients. Navigating this complex terrain is essential for responsible translation of regenerative science into accessible and ethically sound healthcare solutions.
Title : The era of artificial intelligence (AI) and its use in regenerative medicine
Vasiliki E Kalodimou, European University-Cyprus Ltd, Cyprus
Title : The role of gingival fibroblasts in periodontal diseases and regeneration
Katarzyna Gawron, Medical University of Silesia in Katowice, Poland
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Role of textile materials in tissue engineering and regenerative medicine
Gokarneshan Narayanan, SSM College of Engineering (Formerly), India
Title : Induction of neo angiogenesis: A way forward for reversing necrosis in complex wounds in orthopaedic practice
Sandeep Shrivastava, Datta Meghe Institute of Medical Sciences, India
Title : Silk-derived sericin at the interface of atopic dermatitis and wound healing: Modulation of inflammation and epidermal repair
Marek Konop, Medical University of Warsaw, Poland